Shenzhen, China—BGI-Shenzhen (“BGI”) announced today that it, through its wholly-owned subsidiary Beta Acquisition Corporation, has extended its all cash tender offer (the “Offer”) to purchase all outstanding shares of common stock of Complete Genomics, Inc. (NASDAQ: GNOM) (“Complete”) to 12:00 midnight (New York City time) on Friday, January 25, 2013. The Offer was previously scheduled to expire at 12:00 midnight (New York City time) on Friday, January 18, 2013.

BGI and Complete are awaiting approval from the Ministry of Commerce of the People’s Republic of China (the “PRC”) and the State Administration of Foreign Exchange of the PRC regarding BGI’s proposed acquisition of Complete pursuant to the previously announced Agreement and Plan of Merger, dated as of September 15, 2012, among BGI, Beta Acquisition Corporation and Complete.

Except for the extension of the Offer expiration date, all other terms and conditions of the Offer remain unchanged. The Depositary for the Offer has indicated that, as of the close of business on January 18, 2013, approximately 30,620,053 shares, or approximately 86%, of common stock of Complete have been validly tendered in and not withdrawn from the Offer, including shares of common stock of Complete subject to guaranteed delivery procedures.

BGI’s financial advisor is Citi, and its legal counsel is O’Melveny & Myers LLP. Complete’s financial adviser is Jefferies & Company, and its legal counsel is Latham & Watkins LLP.

Stockholders with questions about the Offer, or who need assistance with tendering their shares of common stock of Complete, may call the Information Agent, Innisfree M&A Incorporated, toll-free, at (888) 750-5834.